Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
This facility will design & develop instruments, perform product reliability performance testing and verification
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Subscribe To Our Newsletter & Stay Updated
